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Abstract
Background: Molecular aging biomarkers, such as epigenetic age predictors, predict risk factors of premature aging, and
morbidity/mortality more accurately than chronological age in middle-aged and elderly populations. Yet, it remains
elusive if such biomarkers are associated with aging-related outcomes earlier in life when individuals begin to diverge
in aging trajectories. We tested if the Horvath epigenetic age predictor is associated with pubertal, neuroendocrine,
psychiatric, and cognitive aging-related outcomes in a sample of 239 adolescents, 11.0–13.2 years-old.
Results: Each year increase in epigenetic age acceleration (AA) was associated with 0.06 SD units higher weight-for-age,
0.08 SD units taller height-for-age, -0.09 SD units less missed from the expected adult height, 13 and 16% higher odds,
respectively, for each stage increase in breast/genitals development on the Tanner Staging Questionnaire and pubertal
stage on the Pubertal Development Scale, 4.2% higher salivary cortisol upon awakening, and 18 to 34% higher odds for
internalizing and thought problems on the Child Behavior Checklist (p values < 0.045). AA was not significantly associated
with cognition.
Conclusions: Our findings suggest that already in adolescence, AA is associated with physiological age acceleration,
which may index risk of earlier aging. AA may identify individuals for preventive interventions decades before aging-
related diseases become manifest.
Background
There is an imperative to discover biomarkers of human
aging, driven by demographic shifts and the striking
inter-individual variation in trajectories in aging [1, 2].
Biomarkers of aging would allow more precise quantifi-
cation of true biological age, permitting the identifica-
tion of individuals at risk of aging-related diseases for
preventive interventions decades before disorders be-
come manifest.
Among the most promising molecular biomarkers of
aging are those based on changes in DNA methylation
(DNAm), the covalent addition of a methyl group primar-
ily to cytosine linked to guanine by phosphate (CpG) sites
[3]. Variation in DNAm of 71 CpG sites in the whole
blood [4] and of 353 CpG sites from multiple tissues and
cell types [5] have been identified to predict chronological
age with high accuracy (r > .91); note that the algorithms
involve both increased and decreased methylation of CpG
sites to predict aging. These, Hannum and Horvath epi-
genetic age predictors, demonstrate a median absolute dif-
ference between DNAm age and actual chronological age
of up to 4.9 [4] and 3.5 years [5] and have been validated
in 19–101 [4] and 0–100-year-old [5] individuals, respect-
ively. In middle-aged and elderly individuals, the Horvath
and Hannum-based measures of epigenetic age acceler-
ation (AA) (higher DNAm age than actual chronological
age) were associated with higher body-mass index [6],
lower physical and cognitive fitness [7], Alzheimer’s dis-
ease [8], menopause [9], and increased risk of all-cause
mortality [10, 11].
Studies in middle-aged to elderly populations are, however,
confounded by the often decade-long processes of
aging-related disease and aging in itself. Therefore, studies of
aging might better focus earlier in life, when inter-individual
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differences in aging trajectories start to emerge, but before
most age-related diseases become manifest [12]. Such studies
focusing on AA early in life are scarce. In one study, which
tested associations between the Horvath epigenetic age pre-
dictor at birth, 7 and 17 years and physical growth and devel-
opment among 400 to 1000 UK children, found that higher
AA at birth predicted higher fat mass in childhood and ado-
lescence, faster growth in weight and body mass index
(BMI), slower growth in fat mass, and higher odds of in-
creasing Tanner stage of testes development between child-
hood and adolescence [13]. The same study also found that
AA at age 7 was associated with increased height in child-
hood and adolescence, but slower growth in height between
childhood and adolescence [13], suggesting earlier physio-
logical maturation. In a study of 46 US adolescent girls using
the Horvath epigenetic age predictor, AA at age 13 years was
associated with higher salivary cortisol [14].
There are few data on associations between epigenetic
age and aging-related biomarkers early in life. There is an
absence of literature of other early life phenotypes
well-known to be related to aging-related diseases and/or
premature mortality, namely, psychiatric problems and cog-
nitive functioning [15, 16]. We examined 11.0–13.2-year-
old Finnish adolescents to determine whether the Horvath
epigenetic age predictor is related to the tempo of markers
of physical growth and development, hypothalamic-
pituitary-adrenal (HPA) axis functioning, psychiatric prob-
lems, and cognition. Based on preclinical studies showing
that fetal exposure to excess glucocorticoids ‘programs’ an
offspring phenotype of accelerated risk factors for cardio-
metabolic and psychiatric disorders, likely mediated, in part,
via altered DNAm profiles [17, 18], we hypothesized that
AA would be associated with more advanced physical
growth and development, higher diurnal and lesser sup-
pressed salivary cortisol in response to dexamethasone,
higher total and internalizing and externalizing psychiatric
problems, and lower scores on neuropsychological tests of
intelligence.
Results
Characteristics of the sample are in Table 1. Pearson cor-
relations between DNAm age and chronological age was
0.13 (p = 0.041) (Fig. 1). Pubertal (Pearson’s r |0.28–0.91|),
neuroendocrine (|0.41–0.58| p < 0.001; salivary cortisol
awakening response and nadir r = − 0.02,p = 0.74), psychi-
atric (0.14–0.71 p < 0.05; DSM-IV-oriented somatic and
oppositional defiant problems r = 0.13,p = 0.06), and cog-
nitive (0.48–0.85 p < 0.001) outcomes were correlated. Of
the covariates, none was significantly associated with the
adolescent AA (Additional file 1: Table S1).
AA and physical growth and development
Table 2 shows that in models adjusted for adolescent’s
sex and the first three MDS components (model 1), each
year increase in AA was associated with 0.06 SD unit
higher weight-for-age, 0.08 SD unit taller height-for-age,
and − 0.09 SD units less missed from the target adult
height (p values < 0.02). Also each year increase in AA
was associated with a more advanced Tanner stage of
breast/genitals development and a more advanced pu-
bertal stage on the PDS (13 and 16% odds to increase in
stage per each year increase in AA, respectively; p values
< 0.018). When adjusted for the other covariates (model
2) the associations remained significant (p values <
0.014) except for weight-for-age SD score, which became
non-significant (p = 0.051) (Table 2). When we made ad-
justments for maternal self-reported age at menarche, all
the significant associations remained significant (p <
0.042; data not shown). When corrected for multiple
testing (tests across 7 outcomes), the association with
height-for-age SD score (Bonferroni-corrected p = 0.035)
and own current height-for-age SD score minus
mid-parental target height SD score (Bonferroni-cor-
rected p = 0.007) remained significant.
None of the physical growth associations varied by sex (p
values > 0.052 for sex ×AA interactions; data not shown).
AA and diurnal and dexamethasone suppressed salivary
cortisol
In models adjusting for adolescent’s sex, the first three
MDS components and time at awakening, for each year
increase in AA, salivary cortisol at awakening increased by
4.2% (95% CI 0.6; 7.9, p = 0.021) (Fig. 2). This association
survived covariate adjustments (model 2), and adjust-
ments for the adolescents BMI-for-age SD score (Fig. 2;
p values < 0.02), but not correction for multiple testing
(tests across 4 cortisol outcomes; Bonferroni-corrected p =
0.08). Higher AA also associated with salivary cortisol
awakening response, but this association was sex-specific
(p = 0.02 for sex × AA interaction). Additional file 2: Figure
S1 shows that in boys, for each year increase in AA, salivary
cortisol awakening response decreased by − 4.9% (95% CI
− 10.4; 0.09, p = 0.06), while in girls it increased by 3.1%
(95% CI − 1.0; 7.3, p = 0.11); in neither of the groups was
the change in salivary cortisol awakening response signifi-
cant. There were no other significant associations with the
salivary cortisol parameters (p values > 0.06) and no other
sex interactions (p values> 0.06) (data not shown).
AA and psychiatric problems
Figure 3 shows that after the model 1 covariate adjust-
ments, each year increase in AA was associated with 29%
higher odds for internalizing problems, and 29 and 34%
higher odds for anxious/depressed and withdrawn prob-
lems on the internalizing problems domain, respectively
(p values< 0.008); each year, increase in AA was associ-
ated with 27 and 25% higher odds for DSM-IV oriented
affective and anxiety problems (p values< 0.045); and
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Table 1 Characteristics of the sample
Child characteristics at birth: N Mean/N SD/% Range
Sex (boys) 239 116 48.5
Length of gestation (weeks) 239 40.0 1.3 35.6–42.4
Birth weight (g) 239 3571 472 1890–4995
Birth length (cm) 239 50.3 1.9 43.0–55.0
Birth order 239
First 136 56.9
Second or later 103 43.1
Child characteristics in adolescence:
Chronological age (years) 239 12.4 0.5 11.1–13.2
DNA methylation age (years) 239 12.1 3.1 5.4–22.5
Weight (kg) 238 48.7 10.8 23.2–91.1
Weight-for-age (SD) 238 0.3 1.0 − 3.6 – 3.0
Height (cm) 238 156.2 7.5 134.5–177.0
Height-for-age (SD) 238 0.2 1.0 − 2.7 – 2.5
Body mass index (kg/m2) 238 19.8 3.44 12.8–34.5
Body-mass-index-for-age (SD) 238 0.3 1.0 − 3.1 – 2.7
Target height (SD) 238 173.4 7.6 153.9–191.7
Mid-parental target height (SD) minus
height-for-age (SD)
238 0.5 1.0 − 1.9 – 3.5
Tanner Staging Questionnaire
Pubic hair development 233
I 50 21.5
II 83 35.6
III 71 30.5
IV 29 12.4
Breast/genitalia development 234
I 18 7.7
II 81 34.6
III 83 35.5
IV 52 22.2
Pubertal development scale 236
No development 139 58.9
Development barely begun 74 31.4
Development definitely under way 23 9.7
Diurnal salivary cortisol
ln(upon awakening) 218 1.7 0.6 − 1.7 – 3.6
ln(awakening response) 218 0.4 0.7 − 0.9 – 6.3
ln(Nadir) 218 − 0.9 0.9 − 2.3 – 1.8
ln(response to dexamethasone suppression test) 213 0.4 0.8 −v5.2 – 3.0
Psychiatric problems (> 82nd percentile borderline
clinically significant problems)
222
Total behavior problems 38 17.1
Internalizing problems 18 8.1
Externalizing problems 25 11.3
Intelligence quotient, estimated (M = 100; SD = 15)*
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each year, increase in AA was also associated with 18%
higher odds for thought problems within the domain of
other problems (p = 0.035). When adjusted further for
the other covariates (model 2), the association of AA
with anxiety problems became non-significant (p =
0.07), while the other significant associations remained
unaffected (p values < 0.034) (Fig. 3). When corrected
for multiple testing (tests across 4 internalizing, 6
DSM-IV, and 3 other problems domains), the associa-
tions with internalizing, anxious/depressed, withdrawn,
and affective problems (Bonferroni-corrected p value<
0.018) remained significant.
There were no other significant associations with child
psychiatric problems (p values> 0.09; data not shown),
and no significant sex differences in these associations
(p values> 0.06 for sex × AA interactions; data not
shown).
AA and cognition
There were no significant associations between AA and
estimated intelligence (Additional file 1: Table S2).
Discussion
As we hypothesized, adolescents with higher AA,
meaning higher DNAm age than chronological age, was
associated with more advanced physical growth and de-
velopment, higher salivary cortisol, and higher odds for
Table 1 Characteristics of the sample (Continued)
Child characteristics at birth: N Mean/N SD/% Range
General 235 105.8 14.8 57–140
Verbal 236 111.4 17.2 57–153
Performance 237 100.9 19.7 42–141
Maternal characteristics:
Age at delivery (years) 239 30.4 4.4 20.0–43.0
Weight at delivery (kg) 237 63.4 9.9 45.0–98.0
Height (cm) 239 166.8 5.5 151.0–180.0
Body mass index at delivery (kg/m2) 237 22.8 3.5 16.5–36.0
Mode of delivery 239
Vaginal 214 89.5
Cesarean 25 10.5
Alcohol consumption during pregnancy 239
No 199 83.3
Yes 40 16.7
Smoking during pregnancy 239
No 217 90.8
Yes 22 9.2
Consumption of glycyrrhizin in licorice during pregnancy 239
Low (0–249 mg/week) 174 72.8
Medium (250–499 mg/week) 33 13.8
High (≥ 500 mg/week) 32 13.4
Age at menarche (years) 228
Mothers of girls 120 12.69 1.39 9.0–16.0
Mothers of boys 108 12.70 1.19 10.0–16.0
Paternal/parental characteristics:
Paternal height (cm) 236 180.07 6.38 157.00–200.00
Highest educational level of either parent at child’s
adolescence follow-up
239
Secondary or less 25 10.5
Vocational 59 24.7
University degree 155 64.9
Note: *3, 3, and 7 children had estimated general, verbal, and performance intelligence quotient below 70 because of difficulties in visual processing
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psychiatric problems. Adolescents with higher AA were
heavier- and taller-for-age, and closer to their expected
target adult height, suggesting an earlier growth spurt
and less remaining growth potential. Their pubertal
stage of breast/genital development, according to the
Tanner Staging Questionnaire and of secondary sex
characteristics according to PDS, were also at a more
advanced stage.
The advanced growth and maturation was accompan-
ied by higher salivary cortisol upon awakening, and they
had higher odds for displaying borderline clinically
significant internalizing problems, in particular anxious/
depressed and withdrawn problems, and affective and
anxiety as well as thought problems. While these associ-
ations remained significant after adjustments for a
number of important covariates, including maternal
Fig. 1 A scatterplot with a regression line and 95% confidence intervals showing associations between DNA methylation age and chronological
age in 11.0–13.2-year-old adolescents
Table 2 Associations between epigenetic age acceleration and growth and physical development and in 11.0–13.2-year-old
adolescents
Outcome: Epigenetic age acceleration (years) (unstandardized residual regressing DNA methylation age on chronological
age and blood cell count types)
Model 1 Model 2
B/OR 95% CI p B/OR 95% CI p
Anthropometry
Weight-for-age (SD) 0.06 0.01; 0.11 0.02 0.05 0.00; 0.10 0.051
Height-for-age (SD) 0.08 0.03; 0.13 0.003 0.07 0.02; 0.12 0.01
Body-mass-index-for-age (SD) − 0.04 − 0.01; 0.09 0.15 0.02 − 0.02; 0.07 0.31
Mid-parental target height (SD)
minus height-for-age (SD)
− 0.09 − 0.14; − 0.04 0.001 − 0.09 − 0.14; − 0.03 0.001
Tanner Staging Questionnaire
Pubic hair development (I–IV) 1.09 0.98; 1.21 0.12 1.15 0.99; 1.25 0.07
Breast/genitals development (I–IV) 1.13 1.02; 1.25 0.018 1.15 1.03; 1.29 0.014
Pubertal development scale
Stage (I–III) 1.16 1.02; 1.32 0.015 1.19 1.05; 1.34 0.008
Note: B refers to unstandardized regression coefficient from generalized model with Gaussian reference distribution; OR refers to odds ratio from generalized
linear model with ordinal logistic reference distribution; 95% CI refers to 95% confidence interval
Model 1 is adjusted for adolescent sex and the first three multidimensional scaling components based on genome-wide data; model 2 is adjusted for model 1
covariates plus birth weight, gestational age, parity, delivery mode, maternal age and body mass index at delivery, maternal smoking, alcohol and glycyrrhizin in
licorice use during pregnancy, and highest achieved education of either parent in adolescence follow-up
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pregnancy and child perinatal characteristics and genetic
population structure, only the associations with stature
and with internalizing/affective problems remained sig-
nificant after correction for multiple testing. Yet, the
Bonferroni-correction may be an overly stringent
method to account for the multiple testing problem
here, as the outcomes, within each developmental do-
main were not independent of each other. These results
thus suggest that adolescents whose biological DNAm
age is more advanced than their chronological age dis-
play physiological age acceleration that may indicate risk
of earlier aging.
Our findings are consistent with the life history theory
that suggests that early development and early puberty are
meaningful tradeoffs in conditions of environmental adver-
sity [19, 20]. We suggest that AA and advanced growth and
maturation are indicators of more advanced tempo of aging
processes present from early life onwards. Indeed, more ad-
vanced physical growth and pubertal development have
been shown to predict aging-related diseases, including
cancers [21], cardio-metabolic disorders and their risk fac-
tors [22], and depression [23]. While associations between
cortisol, the effector hormone of the HPA axis, and health
are complex, in general high cortisol concentrations, are as-
sociated with a number of physical and mental health ad-
versities, such as obesity [24], sleep problems [25], anxiety,
and depression [26] in studies in both children and adults.
Moreover, longitudinal studies suggest that high cortisol
levels in late adulthood increase the risk for cardiometa-
bolic disorders and cardiovascular mortality [27, 28]. While
childhood psychiatric problems are associated with a num-
ber of physical health adversities and psychosocial problems
[15], there is evidence that they tend to track into adult-
hood [29]. Even in those children whom psychiatric prob-
lems do not persist into adulthood or are subthreshold
[30], and in those whom childhood psychiatric problems
are parent-rated [31], are at increased risk for adverse adult-
hood outcomes, and hence, are likely more vulnerable for
earlier aging.
Our findings with physical growth agree with one pre-
vious study [13] which demonstrated that higher AA at
age 7 was associated with increased height in childhood
and adolescence. Yet, the study found that higher AA at
age 7 predicted slower, rather than faster height growth
Fig. 2 A scatterplot with a regression line and 95% confidence intervals showing associations between epigenetic age acceleration and salivary
cortisol upon awakening in 11.0–13.2-year-old adolescents. Epigenetic age acceleration is calculated as the residual from a linear regression where
DNA methylation age is regressed on chronological age and adjusted for six cell types. Numbers showing percent increase in salivary cortisol upon
awakening per 1 year increase in epigenetic age acceleration and 95% confidence intervals are derived from generalized linear models with Gaussian
reference distribution and adjusted for three multidimensional scaling components from genome-wide data, adolescent’s sex, and time upon
awakening (model 1); and model 1 plus birth weight, gestational age, parity, delivery mode, maternal age and body mass index at delivery, maternal
smoking, alcohol and glycyrrhizin in licorice use during pregnancy, and highest achieved education of either parent in adolescence follow-up (model
2); and model 2 plus body-mass-index-for-age SD score in adolescence (model 3)
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Fig. 3 (See legend on next page.)
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between childhood and adolescence, and that AA at ages
7 and 17 years was not associated with a number of
markers of pubertal development, including peak height
velocity and the Tanner Staging Questionnaire [13]. The
previous study also found that higher AA at birth pre-
dicted higher fat mass, faster growth in weight and BMI,
slower growth in fat mass, and higher odds of increasing
Tanner stage of testes development between childhood
and adolescence [13]. As DNAm undergoes age-related
changes [32], a potential explanation for the somewhat
discrepant study findings on physical growth and devel-
opment between our and the previous study is the
age-stage at which DNAm and physical growth were
measured. The difference in findings does not, however,
relate to tissue type as both studies measured DNAm in
childhood/adolescence from venous blood. Yet, the
p values in the previous study were at their best around
0.007, and none of the associations would have survived
Bonferroni-correction for multiple testing.
Our findings for salivary cortisol are also in partial
agreement with one previous study in adolescent girls,
which demonstrated that higher AA, measured from
salivary DNA, was associated with higher salivary corti-
sol measured across 2 days. This study did not, however,
account for covariates, except for adolescent’s age at
testing, and neither of the previous studies accounted
for genetic population structure, which is strongly asso-
ciated with methylation profiles [33]. Hence, it remains
unclear if the findings of the latter would have survived
adjustments for important covariates, such as BMI, and
if both of these previous studies would have survived
adjustments for genetic population structure.
Our study also revealed novel findings related to
psychiatric problems, namely, that higher AA was
associated with internalizing/affective-type and thought
problems, but not externalizing-type of problems. This
finding may reflect statistical power, as internalizing
problems in our sample were twice as prevalent as exter-
nalizing problems, or studying adolescents, a time when
a marked rise in internalizing problems is observed [34].
This pattern is, however, congruent with our other
recent study. Interestingly, we have demonstrated that
another epigenetic age biomarker, namely, lower DNAm
gestational age than chronological gestational at birth
predicts higher internalizing, but not externalizing prob-
lems in early childhood, though in a sex-specific manner
such that boys are more vulnerable [35]. AA was not as-
sociated with intelligence. This is somewhat surprising,
as poorer childhood cognitive functioning is predictive
of aging-related diseases, including dementia [16].
Hence, because of the developmental changes in DNAm
[32], we cannot rule out that AA at later developmental
stages will change and become associated with cognitive
function and perhaps change its links to behavioral
problems.
Strengths
The strengths of our study relate to a well-characterized
cohort and availability of a number of aging-related
phenotypes that we measured decades before the
aging-related diseases become manifest. We were also
able to account for a number of early life adversities and
their proxies, such as maternal smoking and alcohol use
during pregnancy, maternal age and BMI at delivery,
mode of delivery, and the adolescent’s birth weight and
gestational age. We also accounted for maternal glycyr-
rhizin in licorice use during pregnancy, which is a potent
inhibitor of the placental glucocorticoid barrier enzyme
(11-beta hydroxysteroid dehydrogenase type 2) and
which may result in fetal overexposure to maternal
circulating glucocorticoids; our study was originally
designed to examine its associations with offspring
developmental outcomes, and it is commonly consumed
in young Finnish women (in our original cohort nearly
50%) [36]. None of these early life factors were signifi-
cantly associated with epigenetic AA in this sample,
which is contrary to what we expected based on previ-
ous findings by us and others showing that these factors
may exert adverse consequences on offspring neurodeve-
lopment and HPA-axis functioning [37, 38]. With regard
to maternal glycyrrhizin use, we have previously shown
in a larger sample of this study cohort that high
maternal intake of glycyrrhizin in licorice during
pregnancy (> 500 mg/week) is associated with slightly
shorter length of gestation [39], poorer performance in
neurocognitive tests at ages 8 and 11–13 [40, 41], higher
odds for having borderline clinically significant externaliz-
ing psychiatric problems at ages 8 and 11–13 [40, 41],
(See figure on previous page.)
Fig. 3 Predicted probability of having borderline clinically significant psychiatric problems (panel a: internalizing problems, panel b: anxius/depressed
problems, panel c: withdrawn problems, panel d: thought problems, panel e: affective problems, panel f: anxiety problems) according to epigenetic
age acceleration in 11.0–13.2-year-old adolescents. Epigenetic age acceleration is calculated as the residual from a linear regression where DNA
methylation age is regressed on chronological age and adjusted for 6 cell types. Odds Ratios (OR) and 95% Confidence Intervals are derived from
generalized linear models with binary logistic reference distribution and adjusted for three multidimensional scaling components from genome-wide
data, and adolescent’s sex (model 1); and model 1 plus birth weight, gestational age, parity, delivery mode, maternal age and body mass index at
delivery, maternal smoking, alcohol and glycyrrhizin in licorice use during pregnancy and highest achieved education of either parent in adolescence
follow-up (model 2)
Suarez et al. Clinical Epigenetics  (2018) 10:96 Page 8 of 12
higher diurnal and stress-induced salivary cortisol profiles
at age 8 [42], and more advanced pubertal maturation in
girls at age 11–13 [41]. Whether maternal intake of glycyr-
rhizin in licorice during pregnancy is associated with other
epigenetic biomarkers than the epigenetic age biomarker
studied here, awaits further investigation.
Limitations
The limitations of our study are the narrow age range of
our sample, and hence, the small magnitude of the correl-
ation between DNAm age and chronological age. The
small magnitude of this correlation is, however, similar to
the other two previous childhood epigenetic age studies
[13, 14]. The narrow age range also limits generalizability
from our findings to samples that differ in age from ours
as DNAm changes with age. Our findings are also limited
to DNAm in one tissue type and our study precludes gen-
eralizations beyond Finnish children. Further, our study
design was cross-sectional which precludes testing devel-
opmental changes and causal inferences. We can neither
address the possibility of selection bias resulting from
sample attrition to genetic analyses. Also measuring
genome-wide methylation with the most recent Illumina
EPIC array that lacks 16 (4.5%) of the 353 CpG sites ori-
ginally needed for Horvath DNAm age calculation which
should be kept in mind when interpreting the study find-
ings. Finally, while we measured psychiatric problems with
a standardized, validated, and widely used mother-report
[43], we cannot rule out potential information-bias em-
bedded in the mother-report. Hence, future studies need
to confirm whether our study findings on psychiatric
problems also pertain to clinical diagnoses.
Conclusions
Our study shows that among 11.0–13.2-year-old adoles-
cents, AA is associated with a number of markers that
index risk for earlier aging, namely, more advanced
physical growth and development, higher salivary corti-
sol upon awakening, and psychiatric problems. Our find-
ings are consistent with the life history theory [19, 20]
and lend credence to the proposition that AA may be
used as a biomarker of aging already early in life [3, 13].
Methods
Study population
Glycyrrhizin in Licorice (GLAKU) is an urban
community-based cohort comprising originally 1049
women and their healthy, singleton infants born in 1998
in Helsinki, Finland [39]. Between 2009 and 2011, all ini-
tial cohort members who had given permission to be
contacted, and whose addresses were traceable (N = 920,
87.70% of the original cohort in 1998) were invited to a
follow-up. Of them, 692 (75.20%) could be contacted by
phone, and 451 (65.20% of those contacted by phone)
participated in a follow-up at the child’s mean age of
12.3 years (SD = 0.5, range 11.0–13.2 years). Of the par-
ticipating adolescents, 243 donated blood for genetic
analyses. After quality control procedures, 239 DNA
samples remained for genetic analyses.
In comparison to those who participated in the
follow-up but who did not donate blood or were ex-
cluded from genetic analyses based on quality control
reasons (n = 212), the analytic sample with DNA (n =
239) had higher weight (mean difference (MD) = 3.27 kg,
p < 0.01), height (MD = 2.72 cm, p < 0.01) and BMI (MD
= 0.69 kg/m2, p = 0.03) at the adolescence follow-up, and
their mothers had higher weight at delivery (MD =
1.76 kg, p = 0.05). The groups did not differ in chrono-
logical age at adolescent follow-up, sex, birth order, body
size at birth, length of gestation, nor did their mothers
differ in licorice or alcohol consumption or smoking
during pregnancy, BMI at delivery or mode of delivery,
age at menarche; their mothers and fathers did not differ
in educational attainment or height (all p values> 0.07).
Ethics Committees of the City of Helsinki and the
Uusimaa Hospital District approved the study protocol.
Written informed consent was obtained from the
mother at birth and from parent/guardian and adoles-
cent at the follow-up.
Adolescent DNA methylation, epigenetic age, and blood
cell count composition
Blood samples were collected, and DNA was extracted ac-
cording to standard procedures. Methylation analyses
were performed at the Max Planck Institute of Psychiatry
in Munich, Germany. DNA was bisulphite-converted
using the EZ-96 DNA Methylation kit (Zymo Research, Ir-
vine, CA). Genome-wide methylation status of over
850,000 CpG sites was measured using the Illumina Infi-
nium MethylationEPIC arrays (Illumina Inc., San Diego,
CA) according to the manufacturer’s protocol. The arrays
were scanned using the iScan System (Illumina Inc., San
Diego, CA). The final dataset contained 812,943 CpGs.
We obtained DNAm-predicted age based on Horvath
method [5] using the online epigenetic clock calculator
(http://labs.genetics.ucla.edu/horvath/dnamage/). This
calculator also incorporates information on blood cell
counts for 6 cell types (granulocytes, monocytes, natural
killer cells, B cells, CD4+ T cells, and CD8+ T cells)
based on the Houseman method [44]. Epigenetic age
was calculated as the unstandardized residual from a lin-
ear regression of DNAm age on chronological age and 6
cell count types.
Adolescent genotyping and multi-dimensional scaling
analysis
Genotyping was performed on Illumina Human
OmniExpress Exome 1.2 bead chip (Illumina Inc., San
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Diego, CA) at the Tartu University, Estonia in September
2014 according to the standard protocols. Genomic
coverage was extended by imputation using the 1000
Genomes Phase I integrated variant set (v3/April 2012;
NCBI build 37/hg19) as the reference sample and IM-
PUTE2 software. Before imputing the following QC, fil-
ters were applied: SNP clustering probability for each
genotype > 95%, Call rate > 95% individuals and markers
(99% for markers with MAF < 5%), MAF > 1%, HWE p >
1*10–6. Moreover, heterozygosity, sex check, and re-
latedness checks were performed and any discrepancies
were removed (N = 2). We performed multi-dimensional
scaling (MDS) analysis on the identity by state matrix of
quality-controlled genotypes. The first three components
depicted the origin admixture and were included as co-
variates in the regression analyses [33]. This information
was available for 221 participants.
Physical growth and development
We used the following three measures of growth and devel-
opment: (i) the difference between the child’s height-for-age
standard-deviation (SD) score based on Finnish growth
charts [45] (using the current measured height without
shoes, measured with a Seca stadiometer) (model 213; Seca
GmbH & Co KG, Hamburg, Germany) and midparental
target height in SD units [46]; this is a measure of
remaining growth potential and, consequently, the timing
of the pubertal growth spurt. (ii) The Tanner Staging Ques-
tionnaire administered by a research nurse. The question-
naire uses schematic drawings of two secondary sex
characteristics (pubic hair development in girls and boys
and breast development in girls and development of geni-
talia in boys) and yields two 5-stage scores ranging from
pre-pubertal (stage I) to post-pubertal (stage V) [47]. (iii)
The Pubertal Development Scale (PDS) is a self-report
questionnaire on secondary sex characteristics (growth
spurt, body hair that is not specifically pubic hair, and skin
changes in girls and boys; menarche and breast develop-
ment in girls; and facial hair and voice change in boys). The
PDS yields one 4-stage score ranging from no development
(I) to full completion of development (IV) [48].
We also measured weight in light clothing without
shoes (model 8; Seca GmbH & Co KG) and calculated
BMI (weight (kg)/height (m2)). We transformed the
values into weight-for-age and BMI-for-age SD scores
based on Finnish growth charts [45].
Diurnal and dexamethasone-suppressed salivary cortisol
Saliva samples were collected using cotton swabs
(Salivette; Sarstedt, Nümbrecht, Germany). The adoles-
cents were asked not to eat, drink, or brush their teeth
30 min before each sample, with an exception of drink-
ing a small amount of water. We also specifically asked
them to restrain from any caffeine including drinks
(coffee, tea, cola). On the first of two consecutive days,
samples were collected upon awakening and 15, 30, 45,
and 60 min thereafter, at 12:00 noon, at 5:00 p.m., and at
bedtime. Dexamethasone was administered after the
bedtime saliva sample, and a sample was collected upon
awakening the next day. We used a low dose of dexa-
methasone (3 μg/kg of total body weight) to detect indi-
vidual variation in hypothalamic-pituitary-adrenal (HPA)
axis suppression [49]. Salivary cortisol concentrations
were determined by solid-phase, time-resolved fluores-
cence immunoassay with fluorometric end-point detec-
tion (DELFIA; Wallac, Turku, Finland). The intraassay
and interassay coefficients of variation varied between
4.0 and 7.7%, and the mean coefficient of variation be-
tween duplicate analyses was 5.9%.
Of the diurnal measures, we used/calculated the fol-
lowing parameters: cortisol at awakening, cortisol awak-
ening response (peak value after awakening minus value
upon awakening), nadir (minimum of diurnal values),
and response to dexamethasone suppression test (value
upon awakening on day two minus value upon awaken-
ing on day one).
Psychiatric problems
Mothers completed the Child Behavior Checklist
(CBCL/6-18), a standardized and validated rating scale
screening for psychiatric problems [43]. The scale is
hierarchically structured, such that it yields a total prob-
lems score, which is first subdivided into internalizing
and externalizing problems scores, and then internaliz-
ing problems score is further subdivided into anxious/
depressed, withdrawn, and somatic complaints scores,
and externalizing problems into rule-breaking and ag-
gressive behavior scores; scores not included in internal-
izing and externalizing problems score, but which are
embedded in the total problems are social, thought, and
attention problems [43]. The CBCL also yields six Diag-
nostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV)-oriented scores, namely,
affective, anxiety, somatic, attention deficit hyperactivity,
conduct, and oppositional-defiant problems scores [43].
Following the CBCL manual, we used the 82nd percent-
ile as the cutoff to identify adolescents with borderline
clinically significant problems [43].
Cognitive function
We used the short form of the Wechsler-Intelligence-
Scale-for-Children-III [50] which included vocabulary,
similarities, block design, and picture arrangement sub-
tests. We used age-standardized scores to estimate
age-standardized total intelligence, and verbal and per-
formance intelligence quotients (IQs) [51].
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Covariates and confounders
All analyses were adjusted for child’s sex and the first
three MDS components to control for population struc-
ture (model 1). We made further adjustments for covari-
ates previously associated with physical growth and
development, salivary cortisol, psychiatric problems, and
cognition in this cohort [41]: the highest educational level
of either parent (secondary or less/vocational/university)
reported at adolescent follow-up, maternal age (years),
and BMI (kg/m2) at delivery calculated from weight and
height derived from medical records, maternal smoking
(no/yes), weekly alcohol (no/yes) and glycyrrhizin in lic-
orice (0–249 mg/week, 250–499 mg/week, ≥ 500 mg/
week) consumption during pregnancy, delivery mode (va-
ginal/cesarean), parity (primiparous/multiparous), gesta-
tional length (weeks) as confirmed by ultrasound scans,
and birth weight (grams) of the adolescent, derived from
birth records (model 2). In addition, we conducted ana-
lyses of pubertal maturation adjusting for maternal
self-reported age at menarche (years) as a crude proxy of
the genetic component of pubertal development. Analyses
of HPA-axis activity were additionally adjusted for time at
awakening and time at dexamethasone intake as well as
for child’s BMI-for-age SD score.
Statistical analyses
We use generalized linear models (GLM) to study associa-
tions between AA and outcomes, specifying Gaussian refer-
ence distribution for continuous (growth anthropometry,
salivary cortisol, cognition), ordinal logistic for categorical
(Tanner stages and PDS), and binary logistic reference dis-
tribution for dichotomous outcomes (psychiatric problems).
All analyses were adjusted for covariates and confounders
as described and we also tested if the associations between
AA on outcomes varied by sex by including sex ×AA inter-
action into the GLMs following main effects of these vari-
ables as the sexes may differ in epigenetic age, pubertal
maturation, and the prevalence and etiology of psychiatric
problems. We also report Bonferroni-corrected p values to
account for multiple testing within each developmental do-
main. Statistical analyses were performed using IBM SPSS
version 24.0.
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